Hyaluronic Acid Viscosupplementation Market Is Projected to Grow at Cagr of 6.36% During the Forecast Period to Reach a Revenue of $2948.78m by 2023

According to the new market research report by Industry ARC titled “Hyaluronic Acid Viscosupplementation Market: By Course of Treatment, By Anatomy, By End User, and By Geography Analysis - Forecast (2018 - 2023),” the global Hyaluronic Acid Viscosupplementation market is driven by the new technological advancements and collaboration strategies adopted by key players globally.

North America dominated the market with a large market share due to the rising number of arthritis patients in the region. The Centers for Disease Control and Prevention (CDC) estimates that one-third of the U.S. population is obese and obese patients have approximately a greater chance of developing knee osteoarthritis than non-obese patients. North Americans see reimbursement and pricing as the decisive factors for the treatment of hyaluronic acid. However, the APAC region is estimated to grow at the highest CAGR of 7.29% over the forecast period.

By Course of Treatment, Single Injection has witnessed large growth due to the fact that it is the most commonly used type of treatment as it has its efficacy lasting up to six months in pain relief from knee osteoarthritis. The demand for HA injection has also increased due to its benefits such as significant pain reduction, and improvement in functioning in patients.

By Anatomy type, the Knee Osteoarthritis segment has been recording growth because of the increasing aging population. An estimated 27 million people suffer from knee osteoarthritis in the U.S., which is a clear indication of the widespread prevalence of the disease. Knee osteoarthritis affects nearly one third of the global geriatric population. 

Bioventus Inc., a Netherland based company that operates in more than 30 countries, offers various types of orthobiologics such as Durolane, Gelsyn 3, and others. The major competitors in this market are LG Chem Ltd., Sanofi Genzyme, Fidia Pharma USA Inc, and Anika Therapeutics, Inc.

1. By Single injection

2. By Multiple Injection

1. Knee Osteoarthritis

2. Hip Osteoarthritis

3. Ankle Osteoarthritis

4. Shoulder Osteoarthritis

1. Hospitals

2. Clinics

3. Ambulatory Surgical Centers 

1. North America

1.1 U.S

1.2 Canada

1.3 Mexico

2. Europe

2.1 U.K

2.2 Germany

2.3 France

2.4 Italy

2.5 Spain 

2.6 Rest of Europe

3. APAC

3.1 China

3.2 Australia

3.3 Japan

3.4 South Korea

3.5 India

3.6 Rest of APAC

4. Rest of World (RoW)

4.1 South America

4.2 Middle East

4.3 Africa